Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

112.37 +4.14 (+3.83%)
Streaming Delayed Price Updated: 12:03 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biontech Se ADR

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
65 66 Next >
Researchers Working On Universal mRNA-Influenza Vaccine Aiming For Baseline Immune Memory For Diverse Strains
Researchers are working on an experimental pan-influenza vaccine based on the famed mRNA technology to provide broad protection. 
Via Benzinga
Is Now the Time for Income Investors to Buy This Big Pharma Stock?
This drugmaker is among the most dominant pharmaceutical companies in the world. 
Via The Motley Fool
7 Stocks on the Perfect 10 List
Companies that have strong quality, value, or growth grades are the stocks to buy once markets recognize their business potential. 
Via InvestorPlace
PFE Stock Could Be the Booster Shot Your Portfolio Needs Now
PFE stock still remains a dirt-cheap dividend darling, even after across-the-board earnings beats and lifted guidance. 
Via InvestorPlace
Jim Cramer Says China's Vaccines 'Don't Work' But Xi Won't Admit It
COVID-19 cases have spiked again in China, sparking fresh lockdown measures in the nation's capital. Jim Cramer has suggested that Chinese President Xi Jinping isn't telling the whole story.  
Via Benzinga
This COVID-19 Vaccine Stock Has More to Offer
The vaccine revenue was nice, but it's time to look ahead. 
Via The Motley Fool
2 Reasons to Buy Pfizer and 1 Reason to Sell
The pharmaceutical company is looking for a future beyond COVID-19 therapies. 
Via The Motley Fool
After Bill Gates Dumps Billions In Berkshire To Buy Microsoft, His Quiet Biotech Portfolio Has Made A New Trade
Bill Gates has two portfolios he makes trades from: the Bill & Melinda Gates Foundation and the Bill & Melinda Gates Foundation Trust. 
Via Benzinga
7 Stocks to Sell Right Now… and 1 to Buy
Although red ink can sometimes bring an opportunity for contrarianism, these (except one) market ideas represent stocks to sell. 
Via InvestorPlace
Pfizer/BioNTech's Omicron Tailored COVID-19 Vaccine Shows Improved Immune Response Against Emerging Omicron Sublineages
Via Benzinga
Market Rally Holds Key Levels, But Breakouts Struggle; Walmart, Target, Nvidia In Focus: Weekly Review
Walmart, Target and Nvidia were key earnings movers. 
Via Investor's Business Daily
Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages
From BioNTech SE
Via GlobeNewswire
Pfizer, BioNTech Take Next Step Toward A Pan-Covid Vaccine — But Is The Demand There?
The biggest question facing the shot is whether there will be demand for it. 
Via Investor's Business Daily
Ukraine Asserts It Does Not Take Blame For Poland Missile Attack, Crypto Exchange Gemini Suffers $485M In Outflows, FTX, Bahamas Regulator Lock Horns Over Control Of Bankruptcy Proceedings: Top Stories Thursday, Nov. 17
CNBC 
Via Benzinga
Pfizer, BioNTech Start Work On Next-Gen COVID-19 Vaccine Candidate For Broader Protection
Via Benzinga
Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection
From BioNTech SE
Via GlobeNewswire
While COVID-19 Drags On, Biotechs Introduce New Treatments & Vaccines to Combat Subvariants
EQNX::TICKER_START (OTCQB:BIXT),(NASDAQ:NVAX),(NYSE:PFE),(NASDAQ:MRNA),(NASDAQ:INO),(NASDAQ:BNTX) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Third COVID-19 Booster or Fifth Dose Not Required Despite Surge In Cases, Australian Health Authorities Say
Australian health authorities have recommended against a fifth COVID-19 vaccine shot despite average daily cases having been 47% higher last week than the week before, said Health Minister Mark Butler... 
Via Benzinga
Moderna Surges On New Omicron Data, Pulling Pfizer, BioNTech Along For The Ride
Its booster led to a 15.1-fold increase in BA.4- and BA.5-blocking antibodies. 
Via Investor's Business Daily
Biotech Sector Gaining Wins Against Pancreatic Cancer with Early Detection and New Therapies
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 14, 2022 – USA News Group – English actor, comedian and Monty Python alumnus Eric Idle credits early detection for his... 
Via FinancialNewsMedia
BioNTech Plans To Set Up Singapore Based mRNA Plant By End Of 2023
Via Benzinga
BioNTech Expands Global Footprint by Acquiring GMP Manufacturing Site to Establish First mRNA Facility in Singapore
From BioNTech SE
Via GlobeNewswire
Repeat COVID-19 Infection Increases Risk Of Acute Outcomes, Long COVID Symptoms, Study Shows
Via Benzinga
Is It Time To Pay Attention To This Acellular Biologic Pioneer That Says Its Clinical Trials Are Cheaper And Easier?
By Ernest Dela Aglanu, Benzinga 
Via News Direct
Exposures COVID-19 Product Safety
Is It Time To Pay Attention To This Acellular Biologic Pioneer That Says Its Clinical Trials Are Cheaper And Easier?
Learn more about Organicell Regenerative Medicine, Inc.from this latest report. 
Via TheNewswire.com
Exposures COVID-19 Product Safety
Europe Approves Sanofi, GSK's Beta Variant Adapted COVID Shot As Booster
Via Benzinga
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union
From BioNTech SE
Via GlobeNewswire
2 Top Healthcare Stocks to Buy Right Now
These two dividend stocks offer 3%-plus dividend yields that are secure. 
Via The Motley Fool
Is It Time To Pay Attention To This Acellular Biologic Pioneer That Says Its Clinical Trials Are Cheaper And Easier?
During the peak of the deadly COVID-19 pandemic, one novel therapeutic that seems to have played an important role in helping save lives was Organicell Regenerative Medicine Inc.’s (OTCMKTS:... 
Via Benzinga
Return To Office: Pfizer To Enforce 2-3 Days In Office Starting January
Pfizer Inc's (NYSE: PFE) CEO Albert Bourla said the U.S. employees would have to return to their workplaces two to three days a week starting in January. 
Via Benzinga
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.